2015 American Transplant Congress
Improved Long-Term Graft Survival in Renal Transplant Recipients With Donor Specific Antibodies (DSA) After Mycophenolic Acid Escalation
Background: DSA formation in post-renal transplant patients is associated with chronic rejection and graft failure. Previous studies in our population indicate DSA formation is a…2015 American Transplant Congress
Incidence and Outcomes of Polyomavirus Infection in 639 Kidney Transplant Recipients: Are High Immunological Risk Characteristics More Relevant Than Specific Induction Or Maintenance Immunosuppressive Regimens?
Introduction. Polyomavirus-associated nephropathy (PVAN) is now recognized as an important cause of graft dysfunction and early kidney transplant loss. Over-immunosuppression is the main risk factor…2015 American Transplant Congress
Safety and Efficacy of Early Everolimus in De Novo Orthotopic Liver Transplantation
Purpose: To study the safety and efficacy of immunosuppression with Everolimus (EVL) within the first month after orthotopic liver transplantation.Patients and methods: Recipients who had…2015 American Transplant Congress
Non-Cytoreductive Immunosuppression Prevents Rejection of Vascularized Composite Allografts
[Background] Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss such as an extremity or face. Immunosuppression-free donor-specific immunological tolerance has been successfully…2015 American Transplant Congress
A Randomized Cross-Over Phase 3b Study of the Pharmacokinetics of Once-Daily Extended Release MeltDose® Tacrolimus (Envarsus® XR) Versus Twice-Daily Tacrolimus in African-Americans (ASERTAA)
The CYP3A5*1 genotype, highly prevalent in African Americans (AA), commonly necessitates higher tacrolimus (tac) dose requirements and may hinder efforts to obtain therapeutic drug levels.…2015 American Transplant Congress
First Dose Tacrolimus Level Is Better Than CYP3A5 Genotyping in Prediction of Target Tacrolimus Dose
Background: Tacrolimus dose highly varies among Asian kidney transplant recipients. This can be explained by variety of CYP3A5 expression. CYP3A5 genotyping is highly recommended for…2015 American Transplant Congress
Expanding the Living Donor Pool: Results of ABO Incompatible Living Related Kidney Transplantation
Background: Organ shortage has led to an increase in living related kidney transplantation. Here we report on our program of expanding the living donor pool…2015 American Transplant Congress
Alloimmune Regulation and Long-Term Allograft Survival Induced by Short-Term Administration of Chinese Medicine Cornus Officinalis and Cuscuta Sinensis Lam
Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, China.
Achieving long-term allograft survival or tolerance without continuously global immunosuppression is a highly desirable goal. This study is to induce long-term allograft survival without long-term…2015 American Transplant Congress
Once-a-Day Administration of CNIs, mTOR and MMF Is Safe in De Novo Renal Transplant Recipients: 1-Year Results of a Pilot Study
Surgery - Renal Transplant Unit, Catholic University of the Sacred Heart, Rome, Italy.
Introduction. The half-lives of Tacrolimus, Everolimus, Cyclosporine and Mofetil Micofenolate (MMF) are respectively: 43, 30, 27 and 18 hours. Once-daily dosing of these drugs is…2015 American Transplant Congress
12-Month Athena Study: Everolimus Vs. Standard Regimen in De Novo Renal Transplant Recipients
1Athena Study Group, Germany; 2Novartis, Pharma, Germany.
Background: Post-kidney transplant (KTx) long-term and full dose/standard calcineurin inhibitor (CNI) use is associated with an increased risk for malignancies, cardiovascular disease, and renal failure.…
- « Previous Page
- 1
- …
- 120
- 121
- 122
- 123
- 124
- …
- 138
- Next Page »